Advertisement

Topics

Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer

08:00 EDT 13 Jun 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-Tisotumab Vedotin to be Evaluated as a Monotherapy in Patients Who Have Relapsed or Progressed After Standard of Care Treatment- -Tisotumab Vedotin Represents Fourth Late-Stage Development Program Added to List of Ongo...

Other Sources for this Article

Seattle Genetics, Inc.
Media:
Monique Greer, 425-527-4641
mgreer@seagen.com
or
Investors:
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com

NEXT ARTICLE

More From BioPortfolio on "Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...